(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/215579 A1

(51) International Patent Classification:

A61P 1/04 (2006.01)	*C07D 471/04* (2006.01)
A61P 1/10 (2006.01)	*C07D 471/14* (2006.01)
A61P 9/10 (2006.01)	*C07D 471/18* (2006.01)
A61P 11/06 (2006.01)	*C07D 487/04* (2006.01)
A61P 17/02 (2006.01)	*C07D 491/048* (2006.01)
A61P 19/02 (2006.01)	*C07D 491/056* (2006.01)
A61P 25/28 (2006.01)	*C07D 495/04* (2006.01)
A61P 27/02 (2006.01)	*C07D 498/04* (2006.01)
A61P 35/00 (2006.01)	*C07D 498/18* (2006.01)
A61P 37/08 (2006.01)	*C07D 513/04* (2006.01)
C07D 231/54 (2006.01)	

(21) International Application Number:
PCT/IB2025/053787

(22) International Filing Date:
10 April 2025 (10.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/633,369	12 April 2024 (12.04.2024)	US
63/757,828	13 February 2025 (13.02.2025)	US
63/774,036	18 March 2025 (18.03.2025)	US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **CHOI, Chulho**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **FENSOME, Andrew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **FUTATSUGI, Kentaro**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **GERSTENBERGER, Brian Stephen**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **GHAHREMANPOUR, Mohammad Mehdi**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **HEPWORTH, David**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **KNOPF, Kevin Michael**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **KUNG, Daniel Wei-Shung**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **LIN, Fang-Yu**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **MASHALIDIS, Ellene Hera**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **MEAR, Sarah Jane**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **PARIKH, Mihir Dineshkumar**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **PERRY, Ian Brooks**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **SMALTZ, Daniel Jonathan**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **SUN, Jianmin**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **THUMA, Benjamin Aaron**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **WANG, Tao**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **WINDSOR, Ian William**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS

(57) Abstract: The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

WO 2025/215579 A1

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*